Omeprazolum [Inn-Latin] en es it fr

Omeprazolum [Inn-Latin] Brand names, Omeprazolum [Inn-Latin] Analogs

Omeprazolum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Omeprazolum [Inn-Latin] Chemical_Formula


Omeprazolum [Inn-Latin] RX_link

Omeprazolum [Inn-Latin] fda sheet

Omeprazolum_[Inn-Latin] FDA

Omeprazolum [Inn-Latin] msds (material safety sheet)

Omeprazolum [Inn-Latin] Synthesis Reference

U. K. Junggren, S. E. Sjostrand, U.S. Pat. 4,255,431 (1979)

Omeprazolum [Inn-Latin] Molecular Weight

345.417 g/mol

Omeprazolum [Inn-Latin] Melting Point

156 oC

Omeprazolum [Inn-Latin] H2O Solubility

82.3 mg/L

Omeprazolum [Inn-Latin] State


Omeprazolum [Inn-Latin] LogP


Omeprazolum [Inn-Latin] Dosage Forms

Oral tablets

Omeprazolum [Inn-Latin] Indication

For the treatment of gastroesophageal reflux disease.

Omeprazolum [Inn-Latin] Pharmacology

Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

Omeprazolum [Inn-Latin] Absorption

Absorption is rapid, absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg.

Omeprazolum [Inn-Latin] side effects and Toxicity

Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.

Omeprazolum [Inn-Latin] Patient Information

PRILOSEC Delayed-Release Capsules should be taken before eating. Patients should be cautioned that the PRILOSEC Delayed-Release Capsule should not be opened, chewed or crushed, and should be swallowed whole.

For patients who have difficulty swallowing capsules, the contents of a PRILOSEC Delayed-Release Capsule can be added to applesauce. One tablespoon of applesauce should be added to an empty bowl and the capsule should be opened. All of the pellets inside the capsule should be carefully emptied on the applesauce. The pellets should be mixed with the applesauce and then swallowed immediately with a glass of cool water to ensure complete swallowing of the pellets. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The pellets should not be chewed or crushed. The pellets/applesauce mixture should not be stored for future use.

Omeprazolum [Inn-Latin] Organisms Affected

Humans and other mammals